Human Medicines European Public Assessment Report (EPAR): Humira, Adalimumab, Spondylitis, Ankylosing,Arthritis, Juvenile Rheumatoid,Uveitis,Colitis, Ulcerative,Psoriasis,Arthritis, Psoriatic,Crohn Disease,Arthritis, Rheumatoid, Date of Authorisation: 07/09/2003, Revision: 69, Status: Authorised

Case Medical Research
doi 10.31525/cmr-6ac724
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Case Journals

Related search

Human Medicines European Public Assessment Report (EPAR): Ventavis, Iloprost, Hypertension, Pulmonary, Date of Authorisation: 15/09/2003, Revision: 26, Status: Authorised

Case Medical Research
2019English

Human Medicines European Public Assessment Report (EPAR): NovoRapid, Insulin Aspart, Diabetes Mellitus, Date of Authorisation: 07/09/1999, Revision: 29, Status: Authorised

Case Medical Research
2019English

Human Medicines European Public Assessment Report (EPAR): Instanyl, Fentanyl, Pain,Cancer, Date of Authorisation: 20/07/2009, Revision: 21, Status: Authorised

Case Medical Research
2019English

Human Medicines European Public Assessment Report (EPAR): Entecavir Mylan, Entecavir, Hepatitis B, Date of Authorisation: 18/09/2017, Revision: 1, Status: Authorised

Case Medical Research
2019English

Human Medicines European Public Assessment Report (EPAR): Atosiban SUN, Atosiban, Premature Birth, Date of Authorisation: 31/07/2013, Revision: 6, Status: Authorised

Case Medical Research
2019English

Human Medicines European Public Assessment Report (EPAR): Mixtard, Insulin Human (rDNA), Diabetes Mellitus, Date of Authorisation: 07/10/2002, Revision: 18, Status: Authorised

Case Medical Research
2019English

Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis

Journal of managed care & specialty pharmacy
Health PolicyPharmacyPharmaceutical Science
2017English

Human Medicines European Public Assessment Report (EPAR): Silodosin Recordati, Silodosin, Prostatic Hyperplasia, Date of Authorisation: 07/01/2019, Status: Authorised

Case Medical Research
2019English

Human Medicines European Public Assessment Report (EPAR): Xgeva, Denosumab, Fractures, Bone,Neoplasm Metastasis, Date of Authorisation: 13/07/2011, Revision: 17, Status: Authorised

Case Medical Research
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy